Back to discover
Disease

Osteomyelitis

Late-stage therapeutic developmentEmerging research
MeSHOsteomyelitis
2
Publications
19
Clinical trials
2023
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Moderate
Key developments
  • 4 clinical trials expected to report results, the earliest in Q4 2026.
Upcoming Milestones
Major developments
Upcoming trial readoutHigh impact
Intramedullary Calcium Sulfate Antibiotic Depot for Prevention of Open Fracture Related Infection: A Randomized Clinical Trial
Results expected Q1 20272026-07-07
Upcoming trial readoutHigh impact
Prophylactic Antibiotic Coated Nail to Prevent Infection: A Clinical Trial
Results expected Q4 20262026-05-26
Clinical Milestones6View
Results expected 4
Recently completed 1
Other updates 1
Activity timeline6

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Besilesomabapproved

Approval — This medicinal product is for diagnostic use only and the approved indication is scintigr… (2010)

Clinical trials

17 sponsors · 1 new · 1 completed in the last 12 months (net +1)

The current development programme across all trial phases.

Clinical programme
19
All trials
6
Active
13
Late-stage
6
Completed
Late-stage studies

Oral Beta-lactams Versus Non-beta-lactamS for Treatment of Lower Extremity Osteomyelitis

Phase 4 · Recruiting · Michael Garron Hospital

Prophylactic Antibiotic Coated Nail to Prevent Infection: A Clinical Trial

Phase 4 · Recruiting · Wake Forest University Health Sciences

Intramedullary Calcium Sulfate Antibiotic Depot for Prevention of Open Fracture Related Infection: A Randomized Clinical Trial

Phase 3 · Recruiting · Wake Forest University Health Sciences

Comparing Optimal Step-down Therapy for Children With Invasive MRSA Trimethoprim-Sulfamethoxazole vs. Clindamycin for the Treatment of Children With Invasive MRSA Infections

Phase 4 · Recruiting · Indiana University

BonE and Joint Infections - Simplifying Treatment in Children Trial

Phase 4 · Recruiting · Murdoch Childrens Research Institute

Dalbavancin For The Treatment Of Gram Positive Osteomyelitis Or Joint Infections Including Prosthetic Hip Or Knee Infections

Phase 4 · Completed · Infectious Diseases Physicians, Inc.
Recruiting

Oral Beta-lactams Versus Non-beta-lactamS for Treatment of Lower Extremity Osteomyelitis

Phase 4 · Recruiting · Michael Garron Hospital

Prophylactic Antibiotic Coated Nail to Prevent Infection: A Clinical Trial

Phase 4 · Recruiting · Wake Forest University Health Sciences

Intramedullary Calcium Sulfate Antibiotic Depot for Prevention of Open Fracture Related Infection: A Randomized Clinical Trial

Phase 3 · Recruiting · Wake Forest University Health Sciences

Comparing Optimal Step-down Therapy for Children With Invasive MRSA Trimethoprim-Sulfamethoxazole vs. Clindamycin for the Treatment of Children With Invasive MRSA Infections

Phase 4 · Recruiting · Indiana University

BonE and Joint Infections - Simplifying Treatment in Children Trial

Phase 4 · Recruiting · Murdoch Childrens Research Institute
Recently completed

CSP #2001 - Investigation of Rifampin to Reduce Pedal Amputations for Osteomyelitis in Diabetics (VA Intrepid)

Phase 4 · Completed · VA Office of Research and Development

Oral-only Antibiotics for Bone and Joint Infections in Children - A Nationwide Randomized Controlled Trial

Phase 4 · Completed · Rigshospitalet, Denmark

Dalbavancin For The Treatment Of Gram Positive Osteomyelitis Or Joint Infections Including Prosthetic Hip Or Knee Infections

Phase 4 · Completed · Infectious Diseases Physicians, Inc.

Phase 1/2 Trial of Ceftaroline for the Treatment of Hematogenously Acquired Staphylococcus Aureus Osteomyelitis in Children

Phase 1/2 · Completed · Baylor College of Medicine

A Multicenter, Randomized, Double-Blinded Comparative Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Daptomycin Versus Active Comparator in Pediatric Subjects With Acute Hematogenous Osteomyelitis Due to Gram-Positive Organisms

Phase 3 · Completed · Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Comparison of Two Antimicrobial Therapy Duration (6 Weeks Versus 12 Weeks)for Spondylodiscitis

Phase 4 · Completed · Assistance Publique - Hôpitaux de Paris

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

First approvals
2010emaApproval — Besilesomab· This medicinal product is for diagnostic use only and the approved indication is scintigraphic imaging, in conjunction with other appropriate imaging modalities, for determining the location of inflammation/infection in peripheral bone in adults with suspected osteomyelitis. Scintimun should not be used for the diagnosis of diabetic foot infection. source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Research activity

2 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20182023
Major themes4
  • Fractures, Open1
  • Methicillin-Resistant Staphylococcus aureus1
  • Osteomyelitis1
  • Staphylococcal Infections1
Leading journals2
  • Frontiers in immunology1
  • Injury1
Leading researchers8
  • Borens O1
  • Chen Y1
  • Fu Y1
  • Kates S1
  • Kuehl R1
  • Lin Z1
  • Liu G1
  • Liu Z1
Affiliations (unnormalised)6
  • AO Research Institute Davos1
  • Division of Infectious Diseases and Hospital Epidemiology1
  • Erasmus University Medical Centre1
  • Guangdong Provincial Key Laboratory of Bone and Cartilage Regenerative Medicine1
  • Lausanne University Hospital1
  • Southern Medical University Nanfang Hospital1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

INFLAMMATION of the bone as a result of infection. It may be caused by a variety of infectious agents, especially pyogenic (PUS - producing) BACTERIA.

Identifiers
MeSHOsteomyelitis
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.